Abstract
The immunoreactive protein for the matrix metalloproteinase-9 (MMP-9) was studied prospectively from the pre-treatment sera of breast carcinoma patients using an enzyme-linked immunoassay (ELISA). The study comprised 71 primary breast carcinoma patients treated in Oulu University Hospital, Finland, between 1988 and 1991. The median follow-up time was over 10 years. Low preoperative serum MMP-9 (<54.5 ng/ml) was found to correlate with a poor relapse-free survival (RFS) in primary breast carcinoma. After 10 years of follow-up only 43% of the patients with low serum MMP-9 were disease-free, whereas 76% of the patients with high serum MMP-9 lived free of the disease (log-rank P=0.008). Low serum MMP-9 also indicated poor RFS in node-negative ( P=0.03), stage I–II ( P=0.01), progesterone receptor negative ( P=0.008) carcinoma as well as in patients <50 years ( P=0.02) with primary breast carcinoma. There was no statistical difference in overall survival. In multivariate analysis, preoperative low serum MMP-9 increases the risk of relapse 3.0-fold during the first 10 years of follow-up in primary breast carcinoma.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
